23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › SANGAMO THERAPEUTICS INC. › 2023-2024

SANGAMO THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and SANGAMO THERAPEUTICS INC.’s Form 8-K, filed June 5, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 13Ballot items
  • 143Asset managers, any item
  • 1,725Fund votes
  • June 4, 2024Meeting date

Results at a glance

Meeting of June 4, 2024: 13 items on SANGAMO THERAPEUTICS INC.’s Form 8-K, filed June 5, 2024: 9 elected · 4 passed (calculated).

Dissent

Significant dissent: 1 director (20.7% against).

Notable dissent: 3 directors (11.7%, 11.6%, 10.0% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025

Explore SANGAMO THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by SANGAMO THERAPEUTICS INC.

These tallies are SANGAMO THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 5, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SANGAMO THERAPEUTICS INC. — official shareholder meeting results, meeting held June 4, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Courtney Beers, PhD. 104,443,77711,180,6531,666,912 --38,717,741 90%Elected—
Elect Director: Robert F. Carey 109,721,8905,869,3131,700,139 --38,717,741 95%Elected—
Elect Director: Kenneth J. Hillan, M.B. 104,440,26711,196,0891,654,986 --38,717,741 90%Elected—
Elect Director: Margaret A. Horn, J.D. 108,722,5556,881,6921,687,095 --38,717,741 94%Elected—
Elect Director: Alexander D. Macrae, M.B., Ch.B., Ph.D. 102,677,99913,424,0261,189,317 --38,717,741 88%Elected—
Elect Director: John H. Markels, Ph.D. 102,086,56913,568,2241,636,549 --38,717,741 88%Elected—
Elect Director: James R. Meyers 103,985,48011,583,3621,722,500 --38,717,741 90%Elected—
Elect Director: H. Stewart Parker 91,662,08723,918,2871,710,968 --38,717,741 79%Elected—
Elect Director: Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M. 104,262,37311,342,8021,686,167 --38,717,741 90%Elected—
2. Approval, on an Advisory Basis, of the Compensation of the Named Executive Officers as Disclosed in the Proxy Statement 101,303,16815,057,209930,965 --38,717,741 87%Passed (calculated)—
3. Approval of the Amended 2018 Plan 107,523,5578,902,456865,329 --38,717,741 92%Passed (calculated)—
4. Approval of Amendment to Restated Certificate to Increase Authorized Number of Shares of Common Stock 107,950,3348,623,071717,937 ---- 93%Passed (calculated)—
5. Ratification of Appointment of Independent Registered Public Accounting Firm 151,112,5724,145,949750,562 ---- 97%Passed (calculated)—

Source: SANGAMO THERAPEUTICS INC., Form 8-K, filed with the SEC on June 5, 2024 — read the filing on EDGAR.

How asset managers voted at the SANGAMO THERAPEUTICS INC. 2023-2024 meeting

143 asset managers disclosed a vote on at least one SANGAMO THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Alexander D. Macrae, M.B., Ch.B., Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 102,677,999AGAINST: 13,424,026

Prior year: 95.2% for (June 1, 2023 meeting) ▼ 6.8 pts

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: Alexander D. Macrae, M.B., Ch.B., Ph.D.

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Alexander D. Macrae, M.B., Ch.B., Ph.D.”): 102,677,999 for, 13,424,026 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 42,307,993 for, 18,515 abstained.

FOR
FOR: 42,307,993ABSTAIN: 18,515
Largest asset managers voting on “To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,564,0090 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Elect Director: Courtney Beers, PhD.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 104,443,777AGAINST: 11,180,653
Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: Courtney Beers, Ph.D.

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Courtney Beers, PhD.”): 104,443,777 for, 11,180,653 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 42,307,993 for, 18,515 abstained.

FOR
FOR: 42,307,993ABSTAIN: 18,515
Largest asset managers voting on “To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,564,0090 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Elect Director: H. Stewart Parker

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%AGAINST
FOR: 91,662,087AGAINST: 23,918,287

Prior year: 80.5% for (June 1, 2023 meeting) ▼ 1.2 pts

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: H. Stewart Parker

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: H. Stewart Parker”): 91,662,087 for, 23,918,287 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 40,622,694 for, 1,685,299 against, 18,515 abstained.

FOR
FOR: 40,622,694AGAINST: 1,685,299ABSTAIN: 18,515
Largest asset managers voting on “To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,722,03766,568 00For
BlackRock4,123,3960 00For
Fidelity3,093,521470,488 00Mixed
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable256,461237,830 00Mixed
Delaware/Macquarie0400,000 00Against
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC0195,000 00Against
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica073,421 00Against
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya053,715 00Against
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock035,760 00Against
Principal Exchange-Traded Funds035,597 00Against

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Elect Director: James R. Meyers

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 103,985,480AGAINST: 11,583,362

Prior year: 95.3% for (June 1, 2023 meeting) ▼ 5.3 pts

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: James R. Meyers

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: James R. Meyers”): 103,985,480 for, 11,583,362 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 42,307,993 for, 18,515 abstained.

FOR
FOR: 42,307,993ABSTAIN: 18,515
Largest asset managers voting on “To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,564,0090 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Elect Director: John H. Markels, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 102,086,569AGAINST: 13,568,224

Prior year: 90.5% for (June 1, 2023 meeting) ▼ 2.2 pts

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: John H. Markels, Ph.D.

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: John H. Markels, Ph.D.”): 102,086,569 for, 13,568,224 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 41,627,191 for, 680,802 against, 18,515 abstained.

FOR
FOR: 41,627,191AGAINST: 680,802ABSTAIN: 18,515
Largest asset managers voting on “To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,142,521421,488 00Mixed
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC0195,000 00Against
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust054,511 00Against
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Elect Director: Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 104,262,373AGAINST: 11,342,802

Prior year: 95.4% for (June 1, 2023 meeting) ▼ 5.2 pts

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: Karen L. Smith, M.D., Ph.D., M.B.A, L.L.M.

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M.”): 104,262,373 for, 11,342,802 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 42,307,993 for, 18,515 abstained.

FOR
FOR: 42,307,993ABSTAIN: 18,515
Largest asset managers voting on “To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,564,0090 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Elect Director: Kenneth J. Hillan, M.B.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 104,440,267AGAINST: 11,196,089

Prior year: 86.9% for (June 1, 2023 meeting) ▲ 3.4 pts

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: Kenneth J. Hillan, M.B., Ch.B.

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Kenneth J. Hillan, M.B.”): 104,440,267 for, 11,196,089 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 42,307,993 for, 18,515 abstained.

FOR
FOR: 42,307,993ABSTAIN: 18,515
Largest asset managers voting on “To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,564,0090 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Elect Director: Margaret A. Horn, J.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 108,722,555AGAINST: 6,881,692

Prior year: 95.7% for (June 1, 2023 meeting) ▼ 1.6 pts

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: Margaret A. Horn, J.D.

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Margaret A. Horn, J.D.”): 108,722,555 for, 6,881,692 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 41,681,702 for, 626,291 against, 18,515 abstained.

FOR
FOR: 41,681,702AGAINST: 626,291ABSTAIN: 18,515
Largest asset managers voting on “To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,142,521421,488 00Mixed
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC0195,000 00Against
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Elect Director: Robert F. Carey

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 109,721,890AGAINST: 5,869,313

Prior year: 95.0% for (June 1, 2023 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: Robert F. Carey

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Robert F. Carey”): 109,721,890 for, 5,869,313 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 42,307,993 for, 18,515 abstained.

FOR
FOR: 42,307,993ABSTAIN: 18,515
Largest asset managers voting on “To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,564,0090 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Approval of Amendment to Restated Certificate to Increase Authorized Number of Shares of Common Stock

Calculated outcomeCAPITAL STRUCTUREPassed (calculated)

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 107,950,334AGAINST: 8,623,071
Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: To approve an amendment of our Seventh Amended and Restated Certificate of Incorporation, as amended, or the Restated Certificate, to increase the total number of shares of our common stock authorized for issuance from 640,000,000 to 960,000,000 shares;

SANGAMO THERAPEUTICS INC.’s own tally for this item (“4. Approval of Amendment to Restated Certificate to Increase Authorized Number of Shares of Common Stock”): 107,950,334 for, 8,623,071 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 41,886,505 for, 440,003 against.

FOR
FOR: 41,886,505AGAINST: 440,003
Largest asset managers voting on “To approve an amendment of our Seventh Amended and Restated Certificate of Incorporation, as amended, or the R” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,142,521421,488 00Mixed
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Approval of the Amended 2018 Plan

Calculated outcomeCOMPENSATIONPassed (calculated)

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 107,523,557AGAINST: 8,902,456
Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: To approve the amendment and restatement of the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan, or the 2018 Plan, to, among other things, increase the aggregate number of shares of our common stock reserved for issuance under the 2018 Plan by 11,000,000 shares;

SANGAMO THERAPEUTICS INC.’s own tally for this item (“3. Approval of the Amended 2018 Plan”): 107,523,557 for, 8,902,456 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 42,105,620 for, 202,373 against, 18,515 abstained.

FOR
FOR: 42,105,620AGAINST: 202,373ABSTAIN: 18,515
Largest asset managers voting on “To approve the amendment and restatement of the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan, or the ” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,564,0090 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS0191,630 00Against
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Approval, on an Advisory Basis, of the Compensation of the Named Executive Officers as Disclosed in the Proxy Statement

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 8 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 101,303,168AGAINST: 15,057,209

Prior year: 87.9% for (June 1, 2023 meeting) ▼ 0.8 pts

Details: description as filed, official tally, votes by 143 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers, or NEOs, as described in the accompanying Proxy Statement;

SANGAMO THERAPEUTICS INC.’s own tally for this item (“2. Approval, on an Advisory Basis, of the Compensation of the Named Executive Officers as Disclosed in the Proxy Statement”): 101,303,168 for, 15,057,209 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 45 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers, or NEOs, as described in t” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,564,0090 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial120,28921,909 00Mixed
AIG/SunAmerica73,4210 00For
Jackson National065,565 00Against
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Fund voting reports, all 45 managers: 42,197,134 for, 110,859 against, 18,515 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 110 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers, or NEOs, as described in t” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH ADVISORS LP19,165,5820 00For
ARMISTICE CAPITAL, LLC18,174,9660 00For
BlackRock4,666,1940 00For
GEODE CAPITAL MANAGEMENT, LLC3,302,7910 00For
DE Shaw1,913,4200 00For
ACADIAN ASSET MANAGEMENT LLC1,869,4110 00For
State Street1,731,0600 00For
Renaissance1,645,9700 00For
Hudson Bay Capital Management LP1,373,5000 00For
JPMorgan1,319,1200 00For
Charles Schwab1,242,7920 00For
HighTower Advisors, LLC781,5430 00For
Nuveen737,4640 00For
Northern Trust659,9590 00For
MELLON INVESTMENTS Corp574,8470 00For
Vanguard497,1440 00For
Fidelity449,2430 00For
Two Sigma430,4690 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST400,0000 00For
MARSHALL WACE, LLP0351,643 00Against
Federated Hermes335,1190 00For
Dimensional0315,019 00Against
Invesco282,5850 00For
T. Rowe Price278,7040 00For
AllianceBernstein237,8300 00For

Institutional-manager reports, all 110 managers: 63,897,231 for, 691,919 against, 75,000 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Public Accounting Firm

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 151,112,572AGAINST: 4,145,949

Prior year: 97.1% for (June 1, 2023 meeting) ▲ 0.2 pts

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024

SANGAMO THERAPEUTICS INC.’s own tally for this item (“5. Ratification of Appointment of Independent Registered Public Accounting Firm”): 151,112,572 for, 4,145,949 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 42,307,993 for, 18,515 abstained.

FOR
FOR: 42,307,993ABSTAIN: 18,515
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the ye” at SANGAMO THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST17,689,3430 00For
Vanguard11,788,6050 00For
BlackRock4,123,3960 00For
Fidelity3,564,0090 00For
Charles Schwab1,242,7920 00For
TIAA716,5280 00For
Equitable494,2910 00For
Delaware/Macquarie400,0000 00For
Federated Hermes335,1190 00For
QUANTITATIVE MASTER SERIES LLC254,0250 00For
Invesco241,5620 00For
BRIDGEWAY FUNDS INC195,0000 00For
MFS191,6300 00For
T. Rowe Price154,1040 00For
Lincoln Financial142,1980 00For
AIG/SunAmerica73,4210 00For
Jackson National65,5650 00For
Bridge Builder Trust62,5910 00For
Zacks Trust61,4720 00For
Pacific Life57,8640 00For
Northern Trust54,5110 00For
Voya53,7150 00For
MASTER INVESTMENT PORTFOLIO35,7960 00For
John Hancock35,7600 00For
Principal Exchange-Traded Funds35,5970 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Largest SANGAMO THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 207,510,076 shares outstanding at the time of that meeting.

Fund voting reports: top SANGAMO THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers, or NEOs, as…”, 2023-2024
#Asset manager % of shares outstanding
1WASATCH FUNDS TRUST 8.52%
2Vanguard 5.68%
3BlackRock 1.99%
4Fidelity 1.72%
5Charles Schwab 0.60%
6TIAA 0.35%
7Equitable 0.24%
8Delaware/Macquarie 0.19%
9Federated Hermes 0.16%
10QUANTITATIVE MASTER SERIES LLC 0.12%
Institutional-manager reports: top SANGAMO THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers, or NEOs, as…”, 2023-2024
#Asset manager % of shares outstanding
1WASATCH ADVISORS LP 9.24%
2ARMISTICE CAPITAL, LLC 8.76%
3BlackRock 2.25%
4GEODE CAPITAL MANAGEMENT, LLC 1.59%
5DE Shaw 0.92%
6ACADIAN ASSET MANAGEMENT LLC 0.90%
7State Street 0.83%
8Renaissance 0.79%
9Hudson Bay Capital Management LP 0.66%
10JPMorgan 0.64%

Reported SANGAMO THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

SANGAMO THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Armistice Capital, LLC20,664,000 9.96%Proxy statement (DEF 14A), proxy filed April 19, 2024
Wasatch Advisors, Inc.20,134,294 9.70%Proxy statement (DEF 14A), proxy filed April 19, 2024
Biogen, Inc.14,652,466 7.06%Proxy statement (DEF 14A), proxy filed April 19, 2024
Vanguard Group11,615,150 5.60%Form 13F, quarter ended March 31, 2024
BlackRock4,556,208 2.20%Form 13F, quarter ended March 31, 2024
Geode Capital3,363,791 1.62%Form 13F, quarter ended March 31, 2024
Alexander D. Macrae3,263,864 1.57%Proxy statement (DEF 14A), proxy filed April 19, 2024
Biogen MA Inc.3,250,000 1.57%Schedule 13G, filed August 16, 2024
D.E. Shaw3,067,435 1.48%Form 13F, quarter ended March 31, 2024
State Street2,751,804 1.33%Form 13F, quarter ended March 31, 2024

Percentages above are of 207,510,076 shares outstanding, as reported by SANGAMO THERAPEUTICS INC. on its Form 10-Q dated May 6, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At SANGAMO THERAPEUTICS INC.'s shareholder meeting held June 4, 2024, in the 2023-2024 proxy season, 143 asset managers reported votes on at least one of its 13 ballot items in their SEC Form N-PX filings, covering 1,725 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers, or NEOs, as… — FOR was 87% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SANGAMO THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 5, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SANGAMO THERAPEUTICS INC.’s 10-Q dated May 6, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

SANGAMO THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.

Cite this page

Proxy Votes Now, “SANGAMO THERAPEUTICS (SGMOQ) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/sangamo-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.